• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Point of Care Diagnostics Testing Market

    ID: MRFR/MED/9161-HCR
    120 Pages
    Rahul Gotadki
    September 2025

    Point of Care Diagnostics Testing Market By Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Hematology Testing, Cancer/Tumor Marker Testing, Urinalysis Testing, Cholesterol, Drugs-of-Abuse Testing), By End User (Hospitals & Clinics, Diagnostic Centers, Homecare/Self Testing), By Mode of Purchase (OTC, Prescription-based), By Platform (Immunoassays, Molecular Diagnostics, Dipsticks), and Region - Forecast to 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Point of Care Diagnostics Testing Market Research Report - Global Forecast till 2032 Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Table of Contents

    Point of Care Diagnostics Testing Market Summary

    The Global Point of Care Diagnostics Testing Market is projected to experience substantial growth from 57.7 USD Billion in 2024 to 157.9 USD Billion by 2035.

    Key Market Trends & Highlights

    Point of Care Diagnostics Testing Key Trends and Highlights

    • The market is expected to grow at a compound annual growth rate of 9.58 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 157.9 USD Billion, indicating a robust expansion.
    • In 2024, the market is valued at 57.7 USD Billion, reflecting a strong foundation for future growth.
    • Growing adoption of point of care diagnostics due to increasing demand for rapid and accurate testing is a major market driver.

    Market Size & Forecast

    2024 Market Size 57.7 (USD Billion)
    2035 Market Size 157.9 (USD Billion)
    CAGR (2025-2035) 9.58%

    Major Players

    Abbott Laboratories (US), Chembio Diagnostics, Inc. (US), Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Siemens Healthineers GmbH (Germany), Becton, Dickinson and Company (US), Danaher Corporation (US), PTS Diagnostics (US), Nova Biomedical (US), Quidel Corporation (US), Sekisui Diagnostics (US), Trinity Biotech (Ireland), Instrumentation Laboratory Company (Werfen) (US), EKF Diagnostics Holdings plc (UK)

    Point of Care Diagnostics Testing Market Trends

    Drivers

      • Increasing demand for COVID-19 POC test kits

    The Global Point of Care Diagnostics Testing Market is poised for substantial growth, driven by advancements in technology and an increasing demand for rapid diagnostic solutions in various healthcare settings.

    U.S. Food and Drug Administration (FDA)

    Point of Care Diagnostics Testing Market Drivers

    Market Trends and Projections

    Government Initiatives and Funding

    Government initiatives and funding significantly impact the Global Point of Care Diagnostics Testing Market Industry, as various health authorities recognize the importance of accessible diagnostic solutions. Investments in point-of-care technologies are being prioritized to improve healthcare delivery, particularly in underserved regions. Programs aimed at enhancing diagnostic infrastructure and training healthcare professionals are being implemented globally. These initiatives not only foster innovation but also encourage collaboration between public and private sectors, ultimately driving market growth. As governments continue to support point-of-care diagnostics, the industry is poised for expansion, aligning with global health objectives.

    Shift Towards Home Healthcare Services

    The Global Point of Care Diagnostics Testing Market Industry is witnessing a notable shift towards home healthcare services, driven by the increasing preference for at-home testing and monitoring. Patients are increasingly opting for convenient testing options that allow them to manage their health from the comfort of their homes. This trend is supported by advancements in telemedicine and mobile health technologies, which facilitate remote consultations and data sharing. As a result, the market is likely to expand, with projections indicating a compound annual growth rate of 9.58% from 2025 to 2035, reflecting the growing acceptance of home-based diagnostic solutions.

    Increasing Prevalence of Chronic Diseases

    The Global Point of Care Diagnostics Testing Market Industry is significantly influenced by the rising prevalence of chronic diseases such as diabetes, cardiovascular disorders, and infectious diseases. As these conditions require continuous monitoring and management, point-of-care testing offers a practical solution for patients and healthcare providers. The ability to conduct tests in various settings, including home care and remote locations, enhances patient compliance and engagement in their health management. This trend is expected to propel market growth, as the demand for accessible and efficient diagnostic solutions continues to rise in response to the global health landscape.

    Rising Demand for Rapid Testing Solutions

    The Global Point of Care Diagnostics Testing Market Industry experiences a surge in demand for rapid testing solutions, driven by the need for timely diagnosis and treatment. Healthcare providers increasingly prefer point-of-care testing due to its ability to deliver results within minutes, facilitating quicker clinical decisions. This trend is particularly evident in emergency departments and outpatient settings, where immediate test results can significantly impact patient outcomes. The market is projected to reach 57.7 USD Billion in 2024, reflecting a growing recognition of the value of rapid diagnostics in enhancing healthcare efficiency and patient care.

    Technological Advancements in Diagnostic Devices

    Technological innovations play a crucial role in the Global Point of Care Diagnostics Testing Market Industry, with advancements in microfluidics, biosensors, and mobile health applications enhancing diagnostic capabilities. These technologies enable the development of more accurate, user-friendly, and portable testing devices. For instance, the integration of artificial intelligence in diagnostic tools is streamlining data analysis and improving result accuracy. As these technologies evolve, they are expected to drive market growth, contributing to an anticipated increase in market value to 157.9 USD Billion by 2035, as healthcare systems worldwide adopt more sophisticated point-of-care solutions.

    Market Segment Insights

    Get more detailed insights about Point of Care Diagnostics Testing Market Research Report - Global Forecast till 2032

    Regional Insights

    Key Companies in the Point of Care Diagnostics Testing Market market include

    Industry Developments

      • In June 2021,DCN Dx(US) acquired the pointofcare diagnostics development company PortaScience Inc. (US). This acquisition will expand the point of care product portfolio of the company.
      • In April 2021,the Indian Institute of Technology Kharagpur (India), an Indian engineering institute,launched a nucleic acid-based pointof care diagnostic devicefor COVID-19 diagnosis.
      • In April 2021,LumiraDx (US), a next-generation point of care diagnostics testing company,announced its merger with CA Healthcare Acquisition (CAHC) (US)in a deal worth USD 5 billion.
      • In March 2021, MatMaCorp (US) launched MYRTA, a handheld real-time POCPCR device for molecular diagnostics.
      • In March 2020, Abbott(US) launched the fastest available molecular pointofcare test to detect the coronavirus in less than 5 minutes.

    Future Outlook

    Point of Care Diagnostics Testing Market Future Outlook

    The Global Point of Care Diagnostics Testing Market is projected to grow at a 9.58% CAGR from 2024 to 2035, driven by technological advancements, increasing demand for rapid testing, and rising healthcare expenditures.

    New opportunities lie in:

    • Develop portable diagnostic devices for remote healthcare settings.
    • Invest in AI-driven analytics for enhanced diagnostic accuracy.
    • Expand partnerships with telehealth platforms to integrate testing solutions.

    By 2035, the market is expected to achieve substantial growth, reflecting a robust demand for innovative diagnostic solutions.

    Market Segmentation

    Point of Care Diagnostics Testing Product Outlook

    • Strips
    • Meters
    • Lancets

    Point of Care Diagnostics Testing End User Outlook

    • Hospitals & Clinics
    • Diagnostic Centers
    • Homecare/Self Testing
    • Others

    Point of Care Diagnostics Testing Platform Outlook

    • Immunoassays
    • Molecular Diagnostics
    • Dipsticks
    • Others

    Point of Care Diagnostics Testing Mode of Purchase Outlook

    • OTC Testing Products
    • Prescription-based testing products

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 52.70 (USD Billion)
    Market Size 2024 57.71 (USD Billion)
    Market Size 2032 119.36 (USD Billion)
    Compound Annual Growth Rate (CAGR) 9.77 % (2024 - 2032)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Base Year 2023
    Market Forecast Period 2024 - 2032
    Historical Data 2019 - 2023
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson & Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US)
      Key Market Opportunities   Increasing healthcare issues increasing population diagnosed
      Key Market Drivers   Increasing demand for COVID-19 POC test kits Risingnumber of chronic disease cases across the globe

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the CAGR for Point of Care Diagnostics Testing Market?

    The Point of Care Diagnostics/Testing Market can expand at 9.77% CAGR by 2032.

    Who are key players of the Point of Care Diagnostics Testing Market?

    Abbott Laboratories (US),Siemens Healthineers GmbH (Germany),Chembio Diagnostics, Inc.(US),Hoffmann-La Roche Ltd (Switzerland),Johnson & Johnson Services, Inc. (US),Becton, Dickinson and Company (US),Danaher Corporation (US),PTS Diagnostics (US),Nova Biomedical (US),QuidelCorporation (US) Are the key players of market

    What is the valuation of the Point of Care Diagnostics Testing Market?

    By 2032, the Point of Care Diagnostics/Testing Market value can exceed USD 119.36 Billion.

    What is the Point of Care Diagnostics Testing Market driver?

    Increasing demand for COVID-19 POC test kits is driving the Point of Care Diagnostics/Testing Market.

    What is the Point of Care Diagnostics Testing Market restrain?

    Increases the potential of rapid medical diagnosis restrain the Point of Care Diagnostics/Testing Market.

    1. REPORT PROLOGUE
    2. MARKET INTRODUCTION
    3. Definition
      1. Scope of the Study
        1. Research Objective
    4. Assumptions
      1. Limitations
    5. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
    6. Primary Interviews and Information Gathering Process
      1. Breakdown of Primary
    7. Respondents
      1. Forecasting Cellulite Type
      2. Market Size Estimation
        1. Bottom-Up Approach
        2. Top-Down Approach
      3. Data Triangulation
      4. Validation
    8. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    9. MARKET FACTOR ANALYSIS
    10. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
        1. Bargaining Power of Buyers
        2. Threat of New Entrants
    11. Threat of Substitutes
      1. Intensity of Rivalry
      2. Value Chain Analysis
      3. COVID-19 Impact Analysis
        1. Market Impact Analysis
        2. Impact
    12. on Supply Chain
      1. Regional Impact
        1. Opportunity and Threat Analysis
    13. GLOBAL Point of Care Diagnostics Testing MARKET, BY PRODUCT
      1. Overview
      2. Glucose Monitoring
    14. Market Estimates & Forecast, by Region, 2022–2030
    15. Market Estimates & Forecast, by Country, 2022–2030
      1. Strips
    16. Market Estimates & Forecast, by Region, 2022–2030
    17. Market Estimates
    18. & Forecast, by Country, 2022–2030
      1. Meters
    19. Market Estimates
    20. & Forecast, by Region, 2022–2030
    21. Market Estimates & Forecast,
    22. by Country, 2022–2030
      1. Lancets
    23. Market Estimates & Forecast,
    24. by Region, 2022–2030
    25. Market Estimates & Forecast, by Country, 2022–2030
      1. Cardiometabolic Monitoring
    26. Market Estimates & Forecast, by Region,
    27. Market Estimates & Forecast, by Country, 2022–2030
      1. Cardiac Marker Testing Products
    28. Market Estimates & Forecast, by
    29. Region, 2022–2030
    30. Market Estimates & Forecast, by Country, 2022–2030
      1. Blood Gas/Electrolyte Testing Products
    31. Market Estimates & Forecast,
    32. by Region, 2022–2030
    33. Market Estimates & Forecast, by Country, 2022–2030
      1. HbA1c Testing Products
    34. Market Estimates & Forecast, by Region,
    35. Market Estimates & Forecast, by Country, 2022–2030
      1. Infectious Disease Testing
    36. Market Estimates & Forecast, by Region,
    37. Market Estimates & Forecast, by Country, 2022–2030
      1. HIV Testing
    38. Market Estimates & Forecast, by Region, 2022–2030
    39. Market Estimates & Forecast, by Country, 2022–2030
      1. Respiratory
    40. Infection Testing
    41. Market Estimates & Forecast, by Region, 2022–2030
    42. Market Estimates & Forecast, by Country, 2022–2030
      1. Hepatitis
    43. Testing
    44. Market Estimates & Forecast, by Region, 2022–2030
    45. Market
    46. Estimates & Forecast, by Country, 2022–2030
      1. Sexually Transmitted
    47. Disease Testing
    48. Market Estimates & Forecast, by Region, 2022–2030
    49. Market Estimates & Forecast, by Country, 2022–2030
      1. Others
    50. Market Estimates & Forecast, by Region, 2022–2030
    51. Market Estimates
    52. & Forecast, by Country, 2022–2030
      1. Coagulation Monitoring
    53. Market Estimates & Forecast, by Region, 2022–2030
    54. Market Estimates
    55. & Forecast, by Country, 2022–2030
      1. PT/INR Testing
    56. Market
    57. Estimates & Forecast, by Region, 2022–2030
    58. Market Estimates &
    59. Forecast, by Country, 2022–2030
      1. ACT/APTT Testing
    60. Market Estimates
    61. & Forecast, by Region, 2022–2030
    62. Market Estimates & Forecast,
    63. by Country, 2022–2030
      1. Pregnancy & Fertility Testing
    64. Market
    65. Estimates & Forecast, by Region, 2022–2030
    66. Market Estimates &
    67. Forecast, by Country, 2022–2030
      1. Hematology Testing
    68. Market Estimates
    69. & Forecast, by Region, 2022–2030
    70. Market Estimates & Forecast,
    71. by Country, 2022–2030
      1. Cancer/Tumor Marker Testing
    72. Market Estimates
    73. & Forecast, by Region, 2022–2030
    74. Market Estimates & Forecast,
    75. by Country, 2022–2030
      1. Urinalysis Testing
    76. Market Estimates &
    77. Forecast, by Region, 2022–2030
    78. Market Estimates & Forecast, by Country,
      1. Cholesterol
    79. Market Estimates & Forecast, by
    80. Region, 2022–2030
    81. Market Estimates & Forecast, by Country, 2022–2030
      1. Drugs-of-Abuse Testing
    82. Market Estimates & Forecast, by Region,
    83. Market Estimates & Forecast, by Country, 2022–2030
      1. Others
    84. Market Estimates & Forecast, by Region, 2022–2030
    85. Market Estimates & Forecast, by Country, 2022–2030
    86. GLOBAL Point
    87. of Care Diagnostics Testing MARKET, BY END USER
      1. Overview
      2. Hospitals
    88. & Clinics
    89. Market Estimates & Forecast, by Region, 2022–2030
    90. Market Estimates & Forecast, by Country, 2022–2030
      1. Diagnostic
    91. Centers
    92. Market Estimates & Forecast, by Region, 2022–2030
    93. Market
    94. Estimates & Forecast, by Country, 2022–2030
      1. Homecare/Self Testing
    95. Market Estimates & Forecast, by Region, 2022–2030
    96. Market Estimates
    97. & Forecast, by Country, 2022–2030
      1. Others
    98. Market Estimates
    99. & Forecast, by Region, 2022–2030
    100. Market Estimates & Forecast,
    101. by Country, 2022–2030
    102. GLOBAL Point of Care Diagnostics Testing MARKET,
    103. BY MODE OF PURCHASE
      1. Overview
      2. OTC Testing Products
    104. Market
    105. Estimates & Forecast, by Region, 2022–2030
    106. Market Estimates &
    107. Forecast, by Country, 2022–2030
      1. Prescription-based testing products
    108. Market Estimates & Forecast, by Region, 2022–2030
    109. Market Estimates
    110. & Forecast, by Country, 2022–2030
    111. GLOBAL Point of Care Diagnostics
    112. Testing MARKET, BY PLATFORM
      1. Overview
      2. Immunoassays
    113. Market
    114. Estimates & Forecast, by Region, 2022–2030
    115. Market Estimates &
    116. Forecast, by Country, 2022–2030
      1. Dipsticks
    117. Market Estimates
    118. & Forecast, by Region, 2022–2030
    119. Market Estimates & Forecast,
    120. by Country, 2022–2030
      1. Molecular Diagnostics
    121. Market Estimates
    122. & Forecast, by Region, 2022–2030
    123. Market Estimates & Forecast,
    124. by Country, 2022–2030
      1. Others
    125. Market Estimates & Forecast,
    126. by Region, 2022–2030
    127. Market Estimates & Forecast, by Country, 2022–2030
    128. GLOBAL Point of Care Diagnostics Testing MARKET, BY REGION
      1. Overview
      2. North America
        1. US
        2. Canada
      3. Europe
    129. Germany
      1. France
        1. UK
        2. Italy
        3. Spain
        4. Rest of Europe
      2. Asia-Pacific
        1. China
    130. India
      1. Japan
        1. South Korea
        2. Australia
    131. Rest of Asia-Pacific
      1. Rest of the World
        1. Middle East
    132. Africa
      1. Latin America
    133. COMPANY LANDSCAPE
      1. Overview
      2. Competitive Analysis
      3. Market Share Analysis
      4. Major Growth
    134. Strategy in the Global Point of Care Diagnostics Testing Market
      1. Competitive
    135. Benchmarking
      1. Leading Players in Terms of Number of Developments in the
    136. Global Point of Care Diagnostics Testing Market
      1. Key developments and
    137. Growth Strategies
      1. New ProductLaunch/Service Deployment
    138. Merger &Acquisitions
      1. Joint Ventures
      2. Major Players Financial
    139. Matrix
      1. Sales & Operating Income, 2020
        1. Major Players
    140. R&D Expenditure, 2020
    141. COMPANY PROFILES
      1. Abbott Laboratories
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Siemens Healthineers GmbH
        1. Company Overview
        2. Product
    142. Offered
      1. Financial Overview
        1. Key Developments
    143. SWOT Analysis
      1. Key Strategies
      2. Chembio Diagnostics, Inc.
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. F. Hoffmann-La Roche Ltd
        1. Company Overview
        2. Product
    144. Offered
      1. Financial Overview
        1. Key Developments
    145. SWOT Analysis
      1. Key Strategies
      2. Johnson & Johnson Services,
    146. Inc.
      1. Company Overview
        1. Product Offered
        2. Financial
    147. Overview
      1. Key Developments
        1. SWOT Analysis
        2. Key
    148. Strategies
      1. Becton, Dickinson and Company
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Danaher Corporation
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      3. PTS Diagnostics
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      4. Nova Biomedical
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      5. Quidel Corporation
        1. Company Overview
        2. Product Offered
        3. Financial
    149. Overview
      1. Key Developments
        1. SWOT Analysis
    150. Key Strategies
      1. Sekisui Diagnostics
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Trinity Biotech
        1. Company Overview
        2. Product Offered
        3. Financial
    151. Overview
      1. Key Developments
        1. SWOT Analysis
    152. Key Strategies
      1. AccuBioTech Co., Ltd.
        1. Company Overview
        2. Product Offered
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
        6. Key Strategies
      2. Instrumentation
    153. Laboratory Company (Werfen)
      1. Company Overview
        1. Product
    154. Offered
      1. Financial Overview
        1. Key Developments
    155. SWOT Analysis
      1. Key Strategies
      2. EKF Diagnostics Holdings
    156. plc
      1. Company Overview
        1. Product Offered
        2. Financial
    157. Overview
      1. Key Developments
        1. SWOT Analysis
    158. Key Strategies
    159. APPENDIX
      1. References
      2. Related
    160. Reports
    161. MARKET SYNOPSIS, 2022–2030
    162. MARKET ESTIMATES &FORECAST, 2022–2030(USD MILLION)
    163. Point of Care Diagnostics Testing MARKET, BYPRODUCT, 2022–2030 (USD MILLION)
    164. (USD MILLION)
    165. OF PURCHASE, 2022–2030 (USD MILLION)
    166. Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    167. OF CARE DIAGNOSTICS/TESTING MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    168. (USD MILLION)
    169. BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    170. of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    171. (USD MILLION)
    172. USER, 2022–2030 (USD MILLION)
    173. Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    174. US: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD
    175. MILLION)
    176. –2030 (USD MILLION)
    177. MARKET, BY END USER, 2022–2030 (USD MILLION)
    178. Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    179. (USD MILLION)
    180. PRODUCT, 2022–2030 (USD MILLION)
    181. Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    182. Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD
    183. MILLION)
    184. –2030 (USD MILLION)
    185. MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    186. Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    187. GERMANY: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030
    188. (USD MILLION)
    189. PLATFORM, 2022–2030 (USD MILLION)
    190. Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    191. Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    192. –2030 (USD MILLION)
    193. MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    194. Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    195. UK: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD
    196. MILLION)
    197. PURCHASE, 2022–2030 (USD MILLION)
    198. Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    199. Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    200. (USD MILLION)
    201. MODE OF PURCHASE, 2022–2030 (USD MILLION)
    202. Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    203. SPAIN: Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030
    204. (USD MILLION)
    205. END USER, 2022–2030 (USD MILLION)
    206. Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    207. SPAIN: Point of Care Diagnostics Testing MARKET, BYPLATFORM2022–2030 (USD
    208. MILLION)
    209. BY PRODUCT, 2022–2030 (USD MILLION)
    210. Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    211. REST OF EUROPE: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE,
    212. –2030 (USD MILLION)
    213. Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    214. Point of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    215. –2030 (USD MILLION)
    216. Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    217. ASIA-PACIFIC: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030
    218. (USD MILLION)
    219. PRODUCT, 2022–2030 (USD MILLION)
    220. Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    221. Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD
    222. MILLION)
    223. –2030 (USD MILLION)
    224. MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    225. Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    226. INDIA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030
    227. (USD MILLION)
    228. PLATFORM, 2022–2030 (USD MILLION)
    229. Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    230. of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    231. –2030 (USD MILLION)
    232. MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    233. of Care Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    234. (USD MILLION)
    235. BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    236. of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    237. (USD MILLION)
    238. BY END USER, 2022–2030 (USD MILLION)
    239. Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    240. (USD MILLION)
    241. MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    242. Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    243. OF PURCHASE, 2022–2030 (USD MILLION)
    244. of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    245. –2030 (USD MILLION)
    246. Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    247. WORLD: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE, 2022–2030
    248. (USD MILLION)
    249. BY PLATFORM, 2022–2030 (USD MILLION)
    250. Diagnostics Testing MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
    251. MIDDLE EAST: Point of Care Diagnostics Testing MARKET, BY END USER, 2022–2030
    252. (USD MILLION)
    253. BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    254. of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    255. (USD MILLION)
    256. END USER, 2022–2030 (USD MILLION)
    257. Testing MARKET, BY MODE OF PURCHASE, 2022–2030 (USD MILLION)
    258. AFRICA: Point of Care Diagnostics Testing MARKET, BY PLATFORM, 2022–2030 (USD
    259. MILLION)
    260. BY PRODUCT, 2022–2030 (USD MILLION)
    261. Care Diagnostics Testing MARKET, BY END USER, 2022–2030 (USD MILLION)
    262. LATIN AMERICA: Point of Care Diagnostics Testing MARKET, BY MODE OF PURCHASE,
    263. –2030 (USD MILLION)
    264. Testing MARKET, BY PLATFORM, 2022–2030 (USD MILLION)
    265. OF CAREDIAGNOSTICS/TESTING MARKET
    266. of Care Diagnostics Testing MARKET
    267. Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    268. Testing MARKET SHARE, BY END USER, 2020 (%)
    269. Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    270. Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    271. Point of Care Diagnostics Testing MARKET SHARE, BY REGION, 2020 (%)
    272. NORTH AMERICAPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020
    273. BY END USER, 2020 (%)
    274. MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    275. Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    276. of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    277. of Care Diagnostics Testing MARKET SHARE, BY END USER, 2020 (%)
    278. of Care Diagnostics Testing MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    279. EUROPEPoint of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    280. BY END USER, 2020 (%)
    281. MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    282. Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    283. OF THE WORLDPoint of Care Diagnostics Testing MARKET SHARE, BY PRODUCT, 2020 (%)
    284. END USER, 2020 (%)
    285. MARKET SHARE, BY MODE OF PURCHASE, 2020 (%)
    286. of Care Diagnostics Testing MARKET SHARE, BY PLATFORM, 2020 (%)
    287. LABORATORIES .: KEY FINANCIALS
    288. GMBH : KEY FINANCIALS
    289. DIAGNOSTICS, INC. : KEY FINANCIALS
    290. REVENUE
    291. F. HOFFMANN-LA ROCHE LTD.: KEY FINANCIALS
    292. LTD.: SEGMENTAL REVENUE
    293. JOHNSON & JOHNSON SERVICES, INC. : SEGMENTAL REVENUE
    294. & JOHNSON SERVICES, INC. : REGIONAL REVENUE
    295. AND COMPANY : KEY FINANCIALS
    296. REVENUE
    297. DANAHER CORPORATION : KEY FINANCIALS
    298. REVENUE
    299. DIAGNOSTICS: KEY FINANCIALS
    300. FINANCIALS
    301. BIOMEDICAL : REGIONAL REVENUE
    302. : REGIONAL REVENUE
    303. SEKISUI DIAGNOSTICS : SEGMENTAL REVENUE
    304. REGIONAL REVENUE
    305. TRINITY BIOTECH : SEGMENTAL REVENUE
    306. LTD.: SEGMENTAL REVENUE
    307. INSTRUMENTATION LABORATORY COMPANY (WERFEN): SEGMENTAL REVENUE
    308. INSTRUMENTATION LABORATORY COMPANY (WERFEN): REGIONAL REVENUE
    309. DIAGNOSTICS HOLDINGS PLC: KEY FINANCIALS
    310. PLC: SEGMENTAL REVENUE

    Point of Care Diagnostics Testing Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Point of Care Diagnostics Testing Market Research Report - Global Forecast till 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study

    Chemicals and Materials